Literature DB >> 11509307

Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire.

V Peto1, C Jenkinson, R Fitzpatrick.   

Abstract

OBJECTIVE: To determine minimally important differences for dimensions of the PDQ-39, a 39-item Parkinson's disease questionnaire. A minimally important difference is defined as the smallest change between two scores that is subjectively meaningful to patients. Data on minimally important differences are essential for the calculation of sample sizes in trials and surveys.
METHODS: We conducted a postal survey of randomly selected members of 13 local branches of the Parkinson's Disease Society, asking them to complete the PDQ-39 on two occasions, 6 months apart. On the first occasion respondents received the PDQ-39, demographic questions and a request to provide their name and address if they were willing to take part in the follow-up survey. After 6 months, we sent those who had agreed another copy of the questionnaire and also asked them to indicate how much change they had experienced since baseline in overall health and in each of the eight domains of the questionnaire.
RESULTS: We calculated minimally important difference for each dimension and the index score for those reporting minor change since baseline. The minimally important difference varied across dimensions.
CONCLUSIONS: These results indicate the minimum magnitude of change that should be sought when designing studies to evaluate change over time in Parkinson's disease. Since minimally important differences differ across dimensions, those designing studies in which sample size calculations are based on the PDQ-39 as an outcome measure should select the dimension which is the primary variable of interest.

Entities:  

Mesh:

Year:  2001        PMID: 11509307     DOI: 10.1093/ageing/30.4.299

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  58 in total

1.  Assessing the bioethical integrity of a clinical trial in surgery.

Authors:  Mark Bernstein
Journal:  Can J Surg       Date:  2004-10       Impact factor: 2.089

2.  Complications among colorectal cancer survivors: SF-6D preference-weighted quality of life scores.

Authors:  Mark C Hornbrook; Christopher S Wendel; Stephen Joel Coons; Marcia Grant; Lisa J Herrinton; M Jane Mohler; Carol M Baldwin; Carmit K McMullen; Sylvan B Green; Andrea Altschuler; Susan M Rawl; Robert S Krouse
Journal:  Med Care       Date:  2011-03       Impact factor: 2.983

3.  Preoperative brain metabolism and quality of life after subthalamic nucleus stimulation in Parkinson's disease.

Authors:  Sophie Langner-Lemercier; Sophie Drapier; Florian Naudet; Nathalie Le Clanche; Jean-François Houvenaghel; Paul Sauleau; Pierre Jannin; Claire Haegelen; Florence Le Jeune; Marc Vérin
Journal:  J Neurol       Date:  2015-01-30       Impact factor: 4.849

4.  Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease.

Authors:  Neil A Kelly; Matthew P Ford; David G Standaert; Ray L Watts; C Scott Bickel; Douglas R Moellering; S Craig Tuggle; Jeri Y Williams; Laura Lieb; Samuel T Windham; Marcas M Bamman
Journal:  J Appl Physiol (1985)       Date:  2014-01-09

5.  Patient-centered integrated healthcare improves quality of life in Parkinson's disease patients: a randomized controlled trial.

Authors:  Carsten Eggers; R Dano; J Schill; G R Fink; M Hellmich; L Timmermann
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

6.  Variations in functioning and disability in multiple sclerosis. A two-year prospective study.

Authors:  Charlotte Ytterberg; Sverker Johansson; Magnus Andersson; Lotta Widén Holmqvist; Lena von Koch
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

Review 7.  Physiotherapy for Parkinson's disease: a comparison of techniques.

Authors:  Claire L Tomlinson; Clare P Herd; Carl E Clarke; Charmaine Meek; Smitaa Patel; Rebecca Stowe; Katherine H O Deane; Laila Shah; Catherine M Sackley; Keith Wheatley; Natalie Ives
Journal:  Cochrane Database Syst Rev       Date:  2014-06-17

8.  Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.

Authors:  Adrian Williams; Steven Gill; Thelekat Varma; Crispin Jenkinson; Niall Quinn; Rosalind Mitchell; Richard Scott; Natalie Ives; Caroline Rick; Jane Daniels; Smitaa Patel; Keith Wheatley
Journal:  Lancet Neurol       Date:  2010-04-29       Impact factor: 44.182

9.  Charting the progression of disability in Parkinson disease: study protocol for a prospective longitudinal cohort study.

Authors:  Leland E Dibble; James T Cavanaugh; Gammon M Earhart; Terry D Ellis; Matthew P Ford; Kenneth B Foreman
Journal:  BMC Neurol       Date:  2010-11-03       Impact factor: 2.474

10.  Design and baseline characteristics of the ParkFit study, a randomized controlled trial evaluating the effectiveness of a multifaceted behavioral program to increase physical activity in Parkinson patients.

Authors:  Marlies van Nimwegen; Arlène D Speelman; Katrijn Smulders; Sebastiaan Overeem; George F Borm; Frank J G Backx; Bastiaan R Bloem; Marten Munneke
Journal:  BMC Neurol       Date:  2010-08-19       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.